Aurobindo Pharma Ltd reported a 10.2% year-on-year decrease in its consolidated net profit for the first quarter of FY26, dropping to Rs 824.2 crore from Rs 918.2 crore in the corresponding quarter of the previous year. This information was disclosed in the company’s regulatory filing. Despite this decline in profit, the pharmaceutical giant witnessed a 4% year-on-year increase in revenue, reaching Rs 7,868 crore compared to Rs 7,567 crore in the same period last year.
While the operating profit remained relatively stable, the EBITDA decreased by 1% to Rs 1,603 crore from Rs 1,619.6 crore. The EBITDA margin also saw a decline, narrowing to 20.3% from 21.4% a year ago, as per the company’s regulatory filing. In terms of business segments, the US formulations segment, a significant contributor, experienced a 1.9% year-on-year decline to Rs 3,488 crore ($408 million) due to destocking and seasonal factors.
Conversely, the European formulations business showcased robust growth of 18%, reaching Rs 2,338 crore (241 million euros). Revenue from growth markets increased by 8.8% to Rs 772 crore ($90 million), while antiretroviral (ARV) sales surged by 55.2% to Rs 355 crore ($41 million). However, revenue from the active pharmaceutical ingredients (API) segment dropped by 16% to Rs 916 crore ($107 million). The company allocated Rs 367 crore for research and development during the quarter, representing 4.7% of total revenue.
Aurobindo Pharma obtained final approval for 14 Abbreviated New Drug Applications (ANDAs) from the US Food and Drug Administration, including one that had previously received tentative approval. Vice-Chairman and Managing Director K. Nithyananda Reddy expressed satisfaction with the company’s performance at the start of the year, highlighting the strong momentum in the European market and the resilience in the US business despite short-term challenges. He emphasized that strategic execution, operational initiatives, and a recent US acquisition would drive growth acceleration.
The company declared an interim dividend of Rs 4 per equity share with August 8 as the record date, and the dividend is set to be disbursed on or before August 21, as mentioned in the regulatory filing. Aurobindo Pharma aims to leverage its operational strategies and recent acquisitions to foster growth despite the challenges faced in the competitive pharmaceutical landscape.
Key Takeaways:
– Aurobindo Pharma’s Q1 net profit decreased by 10.2% to Rs 824.2 crore year-on-year.
– Despite the profit decline, the company’s revenue rose by 4% in the same quarter.
– The US formulations segment saw a decline, while the European formulations business experienced strong growth.
– Aurobindo Pharma received final approval for 14 Abbreviated New Drug Applications (ANDAs) from the US FDA.
Tags: regulatory
Read more on medicaldialogues.in